- Home
- FTS vs INSM Comparison
FTS vs INSM Comparison
Compare FTS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTS
- INSM
- Stock Information
- Founded
- FTS 1885
- INSM 1988
- Country
- FTS Canada
- INSM United States
- Employees
- FTS N/A
- INSM N/A
- Industry
- FTS Electric Utilities: Central
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- FTS Utilities
- INSM Health Care
- Exchange
- FTS Nasdaq
- INSM Nasdaq
- Market Cap
- FTS 26.0B
- INSM 29.0B
- IPO Year
- FTS N/A
- INSM 2000
- Fundamental
- Price
- FTS $50.21
- INSM $183.32
- Analyst Decision
- FTS Hold
- INSM Strong Buy
- Analyst Count
- FTS 1
- INSM 19
- Target Price
- FTS $72.00
- INSM $171.12
- AVG Volume (30 Days)
- FTS 635.7K
- INSM 2.1M
- Earning Date
- FTS 11-04-2025
- INSM 10-30-2025
- Dividend Yield
- FTS 3.52%
- INSM N/A
- EPS Growth
- FTS 6.60
- INSM N/A
- EPS
- FTS 2.49
- INSM N/A
- Revenue
- FTS $8,705,438,970.00
- INSM $447,022,000.00
- Revenue This Year
- FTS $10.34
- INSM $32.08
- Revenue Next Year
- FTS $4.09
- INSM $125.86
- P/E Ratio
- FTS $19.98
- INSM N/A
- Revenue Growth
- FTS 4.22
- INSM 30.34
- 52 Week Low
- FTS $40.32
- INSM $60.40
- 52 Week High
- FTS $52.47
- INSM $197.08
- Technical
- Relative Strength Index (RSI)
- FTS 45.07
- INSM 68.08
- Support Level
- FTS $49.84
- INSM $178.76
- Resistance Level
- FTS $52.47
- INSM $197.08
- Average True Range (ATR)
- FTS 0.63
- INSM 6.98
- MACD
- FTS -0.22
- INSM 1.64
- Stochastic Oscillator
- FTS 21.25
- INSM 67.45
About FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.